ResearchSemaglutide Recommended by NICE as Add-On Option to Reduce Risk of Heart At... Semaglutide Recommended by NICE as Add-On Option to Reduce Risk of Heart At... Read Post »
New Drug ApprovalRegeneron Pharmaceuticals Secures FDA Nod for Extended EYLEA HD Dosing Up t... Regeneron Pharmaceuticals Secures FDA Nod for Extended EYLEA HD Dosing Up t... Read Post »
New Drug ApprovalFDA Converts Tecartus Approval to Full Approval in Mantle Cell Lymphoma Fol... FDA Converts Tecartus Approval to Full Approval in Mantle Cell Lymphoma Fol... Read Post »
Health TidingsTrump Administration Targets Patented Drug Imports with Conditional Tariffs... Trump Administration Targets Patented Drug Imports with Conditional Tariffs... Read Post »
Mergers & AcquisitionsLupin Completes VISUfarma Acquisition, Expands European Ophthalmology Portf... Lupin Completes VISUfarma Acquisition, Expands European Ophthalmology Portf... Read Post »
Clinical TrialsBridgeBio Reports 54-Month Data, Sustained Survival Benefit with Acoramidis... BridgeBio Reports 54-Month Data, Sustained Survival Benefit with Acoramidis... Read Post »
Health TidingsUltragenyx UX111 Nears Decision After FDA Acceptance Ultragenyx UX111 Nears Decision After FDA Acceptance Read Post »
Clinical TrialsImfinzi – Imjudo Regimen Moves Earlier in HCC with EMERALD-3 Data Imfinzi – Imjudo Regimen Moves Earlier in HCC with EMERALD-3 Data Read Post »
Clinical TrialsInnovent, Ollin Report 20-Week JADE Data Showing OLN324 Durability Edge Ove... Innovent, Ollin Report 20-Week JADE Data Showing OLN324 Durability Edge Ove... Read Post »
Clinical TrialsNovo Nordisk’s Indirect Comparison Data from ORION Puts Wegovy Pill and F... Novo Nordisk’s Indirect Comparison Data from ORION Puts Wegovy Pill and F... Read Post »
Health Tidings Mergers & AcquisitionsZai Lab, Amgen Partner to Advance DLL3 Dual-Targeting Strategy in SCLC Zai Lab, Amgen Partner to Advance DLL3 Dual-Targeting Strategy in SCLC Read Post »
Clinical TrialsInnovent’s Mazdutide 9 mg Shows Up to 18.6% Weight Loss in Phase 2 Obesit... Innovent’s Mazdutide 9 mg Shows Up to 18.6% Weight Loss in Phase 2 Obesit... Read Post »
Health TidingsRay Therapeutics Secures RMAT for RTx-015 in RP Ray Therapeutics Secures RMAT for RTx-015 in RP Read Post »
Health TidingsCogent Files NDA for Bezuclastinib in Second-Line GIST, Backed by Phase 3 P... Cogent Files NDA for Bezuclastinib in Second-Line GIST, Backed by Phase 3 P... Read Post »
Health TidingsFDA Expands Vertex’s ALYFTREK and TRIKAFTA Labels to Cover 95% of CF Pati... FDA Expands Vertex’s ALYFTREK and TRIKAFTA Labels to Cover 95% of CF Pati... Read Post »
Clinical TrialsPepGen Highlights Promising Safety and Splicing Trends in Phase 2 DM1 Study PepGen Highlights Promising Safety and Splicing Trends in Phase 2 DM1 Study Read Post »
New Drug ApprovalLilly Brings Weight-Loss Pill to Market with Foundayo FDA Approval Lilly Brings Weight-Loss Pill to Market with Foundayo FDA Approval Read Post »
Health TidingsAgios Plans sNDA Submission for Mitapivat in Sickle Cell Disease Agios Plans sNDA Submission for Mitapivat in Sickle Cell Disease Read Post »
Clinical TrialsOcugen Completes GARDian3 Dosing for OCU410ST in Stargardt Disease Ocugen Completes GARDian3 Dosing for OCU410ST in Stargardt Disease Read Post »
Mergers & AcquisitionsBioVersys Strikes Ansamycin Antibiotic Deal with Hackensack Meridian Health BioVersys Strikes Ansamycin Antibiotic Deal with Hackensack Meridian Health Read Post »
Mergers & AcquisitionsAxsome-Takeda Deal Brings Balipodect into Late-Stage CNS Development Axsome-Takeda Deal Brings Balipodect into Late-Stage CNS Development Read Post »
GenericsFrom Approval to Acceptance: Teva Expands Portfolio with PONLIMSI™ and Xo... From Approval to Acceptance: Teva Expands Portfolio with PONLIMSI™ and Xo... Read Post »
Health TidingsScholar Rock Resubmits Apitegromab BLA to FDA Scholar Rock Resubmits Apitegromab BLA to FDA Read Post »
Drugs Safety AlertFDA Flags Fatal Liver Injury, Including VBDS, with Tavneos (avacopan) FDA Flags Fatal Liver Injury, Including VBDS, with Tavneos (avacopan) Read Post »
Clinical TrialsAstra Zeneca’s Efzimfotase Alfa Shows Phase III Benefit in HPP, With Mixe... Astra Zeneca’s Efzimfotase Alfa Shows Phase III Benefit in HPP, With Mixe... Read Post »
Health Tidings Mergers & AcquisitionsBiogen’s $5.6B Apellis Deal Boosts Immunology and Rare Disease Portfolio Biogen’s $5.6B Apellis Deal Boosts Immunology and Rare Disease Portfolio Read Post »
Health Tidings Mergers & AcquisitionsGalapagos – Gilead Finalize Ouro-Linked Deal to Advance Gamgertamig Galapagos – Gilead Finalize Ouro-Linked Deal to Advance Gamgertamig Read Post »
Clinical TrialsConnect’s Rademikibart Shows Rapid, Sustained FEV1 Improvement Connect’s Rademikibart Shows Rapid, Sustained FEV1 Improvement Read Post »
